drugset / Trial / NCT06475755
Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase II, prospective, randomized, open label, controlled, multi-center study, aim to evaluate the activity of Tislelizumab and Anlotinib and chemotherapy compared with Tislelizumab and chemotherapy before surgery, followed by Tislelizumab alone as adjuvant therapy. The primary objective of this study is to evaluate and compare pathological complete response rate(pCR).
Timeline
- Start
- 2024-06-30
- Primary completion
- 2025-06-10
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 10 mg | Oral |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Albumin-Bound Paclitaxel | Unknown | 130 mg/m2 | Intravenous |
| Background | Albumin-Bound Paclitaxel | Unknown | 260 mg/m2 | Intravenous |
| Background | Carboplatin | Small molecule | 5 unknown | — |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Background | Paclitaxel | Small molecule | 175 mg/m2 | — |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | — |